Abdominal Aortic Aneurysm (AAA): Risk Factors, Rupture, and Management

Definition and Epidemiology

Risk Factors for AAA

Non-Modifiable Risk Factors

Modifiable / Acquired Risk Factors

Special Subtypes and Their Risk Factors

• Inflammatory AAA (5-10% of AAAs): Dense periaortic fibrosis with lymphocytes, plasma cells, macrophages, and giant cells; occurs in younger individuals
• IgG4-related AAA: Tissue fibrosis with IgG4+ plasma cell infiltrate; responds to steroids and anti-B cell therapies; may cause retroperitoneal fibrosis and bilateral hydronephrosis
• Mycotic AAA: Circulating microorganisms (e.g., from infective endocarditis) seed the aneurysm wall, causing suppurative destruction and rapid dilation

Pathobiology

1. Matrix metalloproteinase (MMP) dysregulation - MMP-1, -3, -9, and -13 are elevated in aortic tissue and blood, causing ECM degradation
2. Inflammation - Neutrophils, T cells, B cells, and macrophages all contribute; inflammatory cells serve as additional MMP sources
3. Renin-angiotensin pathway activation
4. Reactive oxygen species overproduction

Risk Factors for Rupture

Size-Based Annual Rupture Risk (Schwartz's Table 23-8)

Other Risk Factors for Rupture

• Uncontrolled hypertension - raises transmural wall stress (Laplace's law: wall tension = pressure × radius)
• Continued cigarette smoking - independently accelerates aneurysmal growth (~2-3 mm/year faster)
• Female sex - associated with higher rupture risk per cm diameter than men
• Rapid expansion - >0.5 cm per year is a warning sign warranting urgent repair regardless of size
• Symptomatic aneurysm - new-onset pain (abdominal, back, or flank) signals expansion or impending rupture; these patients require expeditious evaluation
• Saccular morphology - higher wall stress than fusiform
• COPD/emphysema - may be an independent risk factor for rupture through MMP-mediated mechanisms

Pathological Consequences of Rupture/Complications

• Branch vessel obstruction (renal, mesenteric, iliac arteries) → ischemia
• Thromboembolic events from mural thrombus
• Compression of surrounding structures (ureter, vertebrae)
• Aortoenteric fistula

Gross pathology of ruptured AAA: (A) External rupture site (arrow). (B) Opened aorta - attenuated wall and large layered mural thrombus filling the lumen, with probe demonstrating the rupture tract. - Robbins & Kumar Basic Pathology

Clinical Presentation

• Asymptomatic (most common): Incidental finding on physical examination (pulsatile epigastric mass) or imaging
• Symptomatic (unruptured): Back/abdominal discomfort, often a warning of impending rupture
• Ruptured AAA (classic triad): Sudden severe back/abdominal pain + pulsatile abdominal mass + hypotension/shock

Investigations

• Ultrasound: First-line; reliable for diagnosis and size monitoring; used in screening (UK National AAA Screening Programme offers ultrasound to all men at age 65)
• CT Angiography: Gold standard for pre-operative planning; aorta scanned from arch to pubic symphysis in arterial phase; defines extent, morphology, iliac involvement, and neck anatomy for EVAR planning
• Non-contrast CT: Useful in suspected rupture to detect retroperitoneal haematoma (high attenuation vs. intraluminal blood)
• MR Angiography: Alternative when iodinated contrast is contraindicated
• Bloods: FBC, U&E, LFTs, coagulation studies, lipid profile, cross-match (pre-operatively)

Management

1. Medical / Conservative Management (All Patients)

• Smoking cessation: The most impactful intervention - reduces both rupture risk and aneurysm growth rate
• Antihypertensive therapy: Target aggressive BP control; beta-blockers (e.g., atenolol) and ACE inhibitors/ARBs preferred
• High-intensity statins: Associated with reduced aneurysm growth and rupture in observational studies; also treat dyslipidemia
• No pharmacological therapy has been proven in RCTs to reduce AAA expansion

2. Surveillance (Small AAAs)

3. Indications for Repair

• Diameter ≥5.5 cm in men (fit for surgery)
• Diameter ≥5.0 cm in women (rupture risk per size is higher)
• Rapid expansion ≥0.5 cm/year regardless of size
• Symptomatic aneurysm at any size (expansion, contained leak, tenderness)
• Ruptured AAA - emergency intervention

4. Elective Repair: Open vs. Endovascular

Open Surgical Repair (OSR)

• Transabdominal or retroperitoneal approach
• Aortic cross-clamping above and below the aneurysm
• Resection and replacement with a prosthetic tube graft or bifurcated aorto-iliac graft
• Operative mortality: ~5% electively (higher in emergency)

• Permanent cure - aneurysm sac permanently excluded
• No need for long-term imaging surveillance
• Allows assessment of colonic circulation and exploration of other abdominal pathology

• Cardiac (MI, arrhythmia): 2-6% - most common complication
• Renal failure: <2% elective; >20% after ruptured AAA repair
• Ischemic colitis: Devastating if full-thickness; mortality up to 90%; highest risk after ruptured AAA repair
• Prosthetic graft infection: 1-4%
• Aortoenteric fistula: Years later; presents with massive hematemesis

Endovascular Aneurysm Repair (EVAR)

• Percutaneous/femoral approach; stent graft deployed under fluoroscopic guidance
• Requires suitable anatomy: adequate infrarenal neck length/diameter, non-tortuous iliac access
• Operative mortality: Lower than OSR in the short term

• EVAR has significantly lower perioperative morbidity and mortality
• Beyond ~2 years, overall survival is similar between EVAR and open repair
• Long-term efficacy of EVAR requires ongoing surveillance (lifelong)
• Risk of late aortic rupture after EVAR: >5% over 8 years

• CT angiogram at 1 month (assess for endoleaks, stent position)
• 12-month CT
• Annual thereafter (duplex ultrasound if 1-month CT is clean)

• Type I (inadequate seal at graft end) - most dangerous, requires re-intervention
• Type II (retrograde filling via branch vessel e.g., lumbar, IMA) - commonest; may self-resolve; treat if sac enlarges
• Types III-V - less common; Type III (graft defect) requires re-intervention

5. Emergency Management of Ruptured AAA

1. Large-bore IV access, blood cross-match, activate massive transfusion protocol
2. Permissive hypotension (target systolic BP ~70-90 mmHg) to minimize further hemorrhage while awaiting repair
3. CT angiography urgently if patient is haemodynamically stable enough; reveals retroperitoneal haematoma
4. Inform surgical, anaesthetic, and theatre teams simultaneously

• Emergency EVAR (if anatomy suitable and available): Increasingly preferred for stable-enough patients; reduces operative mortality compared to open
• Emergency open repair: Required when EVAR is not anatomically feasible or in extremis
• The key determinant of outcome is the patient's condition on arrival, speed of diagnosis, and operative precision

6. Special Situations

• Inflammatory AAA: Same repair thresholds; periaortic fibrosis makes open dissection more difficult - EVAR preferred if anatomy allows; corticosteroids for IgG4-related subtype
• Mycotic AAA: Either OSR or EVAR acceptable; long-term antibiotic therapy mandatory if EVAR chosen to prevent recrudescence
• High surgical risk / unfit patients: EVAR in the EVAR-2 trial showed that it is not beneficial in patients unfit for open repair, as all-cause mortality offsets aneurysm-related benefit

Summary Table

References: Goldman-Cecil Medicine 25e, pp. 728-730; Schwartz's Principles of Surgery 11e, pp. 919-925; Bailey & Love's Short Practice of Surgery 28e, p. 1038-1039; Robbins & Kumar Basic Pathology 10e, p. 333.

Evaluation and Management of Calf Pain on Walking in a 50-Year-Old Diabetic, Obese Male

Clinical Diagnosis: Intermittent Claudication (IC) Due to Peripheral Artery Disease (PAD)

"At 32%, 5-year mortality in PAD is higher than that for many cancers." - Sabiston Textbook of Surgery

Pathophysiology

• Diabetes mellitus: Accelerates atherosclerosis, promotes distal/tibial vessel disease, and causes peripheral neuropathy that can mask symptoms, making clinical assessment unreliable. Diabetic patients often present at more advanced stages.
• Obesity (BMI 31): Contributes to insulin resistance, dyslipidaemia, hypertension, and systemic inflammation - all driving atherosclerosis
• Male sex + age >50: Classic high-risk demographic

Classification (Staging)

EVALUATION

1. History

• Exact walking distance before onset (claudication distance)
• Location of pain (calf = SFA/popliteal disease; thigh/buttock = aorto-iliac disease; Leriche syndrome)
• Time to resolution after rest (typically <5 minutes in vascular claudication)
• Progression over time

• Duration and control of diabetes (HbA1c, medications)
• Smoking history (most powerful modifiable risk factor)
• Hypertension duration/control
• Dyslipidaemia
• Family history of premature cardiovascular disease
• Prior MI, stroke, TIA

• Rest pain (forefoot, worse with elevation, relieved by dependency - suggests critical limb ischaemia)
• Non-healing wounds/ulcers
• Erectile dysfunction (suggests aorto-iliac/Leriche syndrome)

2. Physical Examination

• Pulse palpation at all levels: carotid, brachial, radial, femoral, popliteal, dorsalis pedis (DP), posterior tibial (PT) - bilaterally compared; diminished or absent pulses at any level guides localisation of disease
• Auscultation for bruits: neck (carotid), abdomen (renal/mesenteric), femoral region - suggests turbulent flow across a stenosis
• Capillary refill time and skin temperature
• Buerger's test: Legs elevated 45° → pallor in ischaemia; placed dependent → reactive hyperaemia (Buerger's angle <20° is severe)
• Skin changes: Pallor, dependent rubor, elevation pallor, loss of hair growth, dry/shiny skin, apocrine gland dysfunction, muscle atrophy
• Ulcers or gangrene: Ischaemic ulcers are typically painful, punched-out, over pressure points, with pale sloughy base (vs. neuropathic ulcers = painless, plantar surface)

• Semmes-Weinstein monofilament test (10g) for protective sensation
• Vibration sense (128 Hz tuning fork), proprioception
• Tendon reflexes

• BP both arms (>15 mmHg difference suggests subclavian/aortic disease)
• BMI, waist circumference
• Fundoscopy (diabetic retinopathy as marker of microvascular disease)
• Cardiac examination (concurrent CAD is common)

3. Investigations

First-Line / Non-Invasive

"ABI results should be uniformly reported, with noncompressible values defined as >1.40, normal 1.00-1.40, borderline 0.91-0.99, and abnormal ≤0.90." - Goldman-Cecil Medicine, p. 770

Second-Line / Anatomical Imaging (When Planning Intervention)

• CT Angiography (CTA): Excellent for aortoiliac and femoropopliteal segments; calcification creates artefact in distal tibial vessels (problematic in diabetes)
• MR Angiography (MRA): Most accurate for detecting >50% stenosis; better for infrapopliteal vessels in diabetics; avoids iodinated contrast; contraindicated with ferromagnetic implants; gadolinium risk if GFR <60 mL/min
• Digital Subtraction Angiography (DSA): Invasive gold standard; reserved for when intervention is planned concurrently

Laboratory Investigations

MANAGEMENT

1. Risk Factor Modification (Most Important Intervention)

Smoking Cessation

Glycaemic Control

Hypertension Management

Dyslipidaemia / Statin Therapy

• Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg daily
• Target LDL <1.4 mmol/L (<55 mg/dL) in very high cardiovascular risk
• If target not achieved, add ezetimibe; PCSK9 inhibitors (evolocumab) have demonstrated reduced limb events in PAD (FOURIER trial)

Weight Reduction

2. Antiplatelet / Antithrombotic Therapy

• Clopidogrel is preferred over aspirin in established PAD (CAPRIE trial data)
• Dual pathway inhibition with rivaroxaban 2.5 mg BD + aspirin 100 mg has demonstrated reduced major adverse limb events in PAD (COMPASS trial) but increases bleeding risk - suitable in selected high-risk patients

3. Exercise Therapy

• Programs typically involve 30-60 minutes of treadmill walking, 3 sessions/week for 12 weeks
• Mechanism: improved collateral formation, skeletal muscle adaptation, enhanced oxygen extraction, improved endothelial function, and metabolic efficiency
• Increases pain-free walking distance significantly
• Evidence grade A (multiple RCTs)
• Home-based walking programs (using wearables + telephone coaching) are an effective alternative (HONOR trial, LITE trial)

"Supervised exercise therapy is of benefit in reducing claudication and increasing pain-free walking distance." - Katzung's Basic and Clinical Pharmacology, p. 324

4. Pharmacotherapy for Claudication

Cilostazol (First-Line)

• Phosphodiesterase III inhibitor; vasodilator + antiplatelet
• 100 mg twice daily for 3-month trial
• Based on Cochrane review of 16 RCTs: significantly improves pain-free and maximum walking distance
• Contraindicated in heart failure (all PDEI3 drugs increase mortality in CHF)
• Side effects: headache, diarrhoea, dizziness, palpitations

Naftidrofuryl (available in UK/Europe)

• 5-HT₂ antagonist; similar efficacy to cilostazol
• 200 mg three times daily

Not Recommended:

• Conventional vasodilators: Of no benefit because distal vessels are already maximally dilated at rest
• Pentoxifylline: Not recommended (insufficient efficacy evidence); previously used as a rheological agent

5. Management Algorithm: When to Consider Revascularisation

1. IC is lifestyle-limiting despite ≥3 months of optimal medical therapy + supervised exercise
2. Critical limb-threatening ischaemia (CLTI) - rest pain (Fontaine III), ulceration, or gangrene (Fontaine IV) - these are urgent indications
3. Short-distance claudication causing significant disability

"Abdominal aortic aneurysms should be repaired when the risk exceeds the risk of perioperative complications. Endovascular repair is preferred in patients with suitable anatomic morphology." - Schwartz's

If Revascularisation Becomes Necessary:

• Percutaneous transluminal angioplasty (PTA) with or without stenting
• Drug-eluting balloons/stents (paclitaxel/limus-coated) reduce restenosis
• Atherectomy for calcified lesions
• Less invasive, lower procedural risk, shorter recovery

• Aorto-femoral bypass (prosthetic Dacron/ePTFE graft) for aortoiliac disease
• Femoro-popliteal bypass with autologous reversed saphenous vein (preferred conduit) or prosthetic graft
• Femoro-distal (tibial) bypass for infrapopliteal disease (common in diabetics)
• Endarterectomy for common femoral artery disease

6. Diabetic Foot Care (Specific to This Patient)

• Regular podiatry review
• Patient education: daily foot inspection, appropriate footwear, moisture management
• Screen for neuropathy (monofilament + vibration)
• Prompt referral for any foot wound or ulcer
• Multidisciplinary diabetic foot team if complications develop

Summary Flowchart

50M, DM, BMI 31, Calf Pain @ 1 km
          ↓
DIAGNOSIS: Intermittent Claudication (Fontaine IIa-IIb)
          ↓
INVESTIGATIONS:
• ABI (if >1.4 → Toe-Brachial Index)
• Segmental pressures + PVR
• Labs: HbA1c, lipids, eGFR, ECG
          ↓
STAGING CONFIRMED (ABI likely 0.5-0.7)
          ↓
MANAGEMENT (IMMEDIATE):
1. Risk factor modification
   - Smoking cessation
   - Glycaemic control (HbA1c <7%)
   - High-intensity statin (atorvastatin 80 mg)
   - BP control (<130/80 mmHg; ACEi/ARB)
   - Weight loss
2. Antiplatelet: Clopidogrel 75 mg/day
3. Supervised Exercise Therapy (12 weeks)
4. Cilostazol 100 mg BD (if no CHF)
5. Diabetic foot care
          ↓
REASSESS AT 3 MONTHS:
Symptoms improved? → Continue medical Rx
Symptoms limiting lifestyle? → Consider revascularisation
(Duplex ultrasound → CTA/MRA → DSA + intervention)

Key References: Sabiston Textbook of Surgery (The Biological Basis of Modern Surgical Practice), pp. 2299-2307; Goldman-Cecil Medicine 25e, pp. 769-771; Schwartz's Principles of Surgery 11e, p. 982; Katzung's Basic and Clinical Pharmacology 16e, p. 324.